| Acquisitions | NOTE 5. ACQUISITIONS For each of the acquisitions described below, except for Boca Pharmacal LLC (Boca), Paladin, Sumavel ® DosePro ® (Sumavel ® ), Somar Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable (Somar), DAVA Pharmaceuticals, Inc. (DAVA) and Natesto™, the estimated fair values of the net assets acquired below are provisional as of September 30, 2015 and are based on information that is currently available to the Company. Additional information is being gathered to finalize these provisional measurements. Accordingly, the measurement of the assets acquired and liabilities assumed may change upon finalization of the Company’s valuations and completion of the purchase price allocations, all of which are expected to occur no later than one year from the respective acquisition dates. Paladin Labs Inc. Acquisition On February 28, 2014 (the Paladin Acquisition Date), the Company, through a Canadian subsidiary, acquired all of the shares of Paladin and a U.S. subsidiary of the Company merged with and into EHSI, with EHSI surviving the merger. As a result of these transactions, the former shareholders of EHSI and Paladin became the shareholders of Endo, a public limited company organized under the laws of Ireland, and both EHSI and Paladin became our indirect wholly-owned subsidiaries. Under the terms of the transaction, former Paladin shareholders received 1.6331 shares of Endo stock, or 35.5 million shares, and C$1.16 in cash, for total consideration of $2.87 billion as of February 28, 2014. On the Paladin Acquisition Date, each then current EHSI shareholder received one ordinary share of Endo for each share of EHSI common stock owned upon closing. Immediately following the closing of the transaction, former EHSI shareholders owned approximately 79% of Endo, and former Paladin shareholders owned approximately 21% . The acquisition consideration was as follows (in thousands, except for per share amounts): Number of Paladin shares paid through the delivery of Endo International ordinary shares 20,765 Exchange ratio 1.6331 Number of ordinary shares of Endo International—as exchanged* 33,912 Endo International ordinary share price on February 28, 2014 $ 80.00 Fair value of ordinary shares of Endo International issued to Paladin Shareholders* $ 2,712,956 Number of Paladin shares paid in cash 20,765 Per share cash consideration for Paladin shares (1) $ 1.09 Cash distribution to Paladin shareholders* 22,647 Fair value of the vested portion of Paladin stock options outstanding—1.3 million at February 28, 2014 (2) 131,323 Total acquisition consideration $ 2,866,926 __________ * Amounts do not recalculate due to rounding. (1) Represents the cash consideration per the arrangement agreement of C$1.16 per Paladin share translated into U.S. dollars utilizing an exchange rate of $0.9402 . (2) Represents the fair value of vested Paladin stock option awards attributed to pre-combination services that were outstanding on the Paladin Acquisition Date and settled on a cash-less exercise basis for Endo shares. Paladin is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring and in-licensing innovative pharmaceutical products for the Canadian and world markets. Paladin’s key products serve growing therapeutic areas including attention deficit hyperactivity disorder (ADHD), pain, and urology. In addition to its Canadian operations, as of the Paladin Acquisition date, Paladin owned a controlling interest in Laboratorios Paladin de Mexico S.A. in Mexico and in publicly traded Litha Healthcare Group Limited (Litha) in South Africa. The operating results of Paladin are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and the operating results from the acquisition date of February 28, 2014 are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2014 . The Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014 reflect the acquisition of Paladin, effective February 28, 2014 . Our measurement period adjustments for Paladin were complete as of February 28, 2015 . In connection with the finalization of our measurement period adjustments for Paladin, we recorded a decrease to certain deferred tax assets of $1.4 million , with a corresponding increase to goodwill. Other than these adjustments, there have been no changes to the fair values of the assets acquired and liabilities assumed at the Paladin Acquisition Date from what was disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014 , filed with the Securities and Exchange Commission on March 2, 2015. Goodwill arising from the Paladin acquisition has been assigned to multiple reporting units across each of the Company’s reportable segments based on the relative incremental benefit expected to be realized by each impacted reporting unit. The Company recognized acquisition-related transaction costs associated with the Paladin acquisition during the nine months ended September 30, 2014 totaling $33.4 million . These costs, which related primarily to bank fees, legal and accounting services, and fees for other professional services, are included in Acquisition-related and integration items in the accompanying Condensed Consolidated Statements of Operations . There were no acquisition-related transaction costs associated with the Paladin acquisition during the nine months ended September 30, 2015 . The amounts of Paladin Revenue and Net income attributable to Endo International plc included in the Company’s Condensed Consolidated Statements of Operations from and including February 28, 2014 to September 30, 2014 are as follows (in thousands, except per share data): Revenue $ 165,852 Net income attributable to Endo International plc $ 15,201 Basic net income per share $ 0.11 Diluted net income per share $ 0.10 The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Paladin had occurred on January 1, 2014 for the nine months ended September 30, 2014 . This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2014 , nor are they indicative of any future results. Nine Months Ended September 30, 2014 Unaudited pro forma consolidated results (in thousands, except per share data): Revenue $ 1,884,573 Net loss attributable to Endo International plc $ (678,399 ) Basic net (loss) per share $ (4.69 ) Diluted net (loss) per share $ (4.35 ) These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Paladin to reflect factually supportable adjustments that give effect to events that are directly attributable to the Paladin acquisition assuming the Paladin acquisition had occurred January 1, 2014 . These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition which decreased the expense by $1.0 million for the nine months ended September 30, 2014 . The adjustments to additional intangible amortization, net of tax, that would have been charged assuming the Company’s estimated fair value of the intangible assets, increased the expense by $3.6 million for the nine months ended September 30, 2014 . Acquisition of Remaining Shares of Litha In February 2015, Paladin acquired substantially all of Litha’s remaining outstanding ordinary share capital that it did not own for consideration of approximately $40 million . At December 31, 2014 , our Paladin subsidiary owned 70.3% of the issued ordinary share capital of Litha. In connection with this transaction, Paladin had deposited cash into an escrow account, primarily for the purpose of guaranteeing amounts required to be paid to Litha’s security holders in connection with this acquisition. The balance in this account at December 31, 2014 of approximately $40 million was included in Restricted cash and cash equivalents in the Condensed Consolidated Balance Sheets and was subsequently paid in February 2015. Refer to Note 14. Shareholders' Equity for further information. Boca Pharmacal LLC Acquisition On February 3, 2014 , the Company acquired Boca Pharmacal LLC for $236.6 million in cash. Boca is a specialty generics company that focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions. The fair values of the net identifiable assets acquired totaled $212.3 million , resulting in goodwill of $24.3 million , which was assigned to our U.S. Generic Pharmaceuticals segment. The amount of net identifiable assets acquired in connection with the Boca acquisition includes $140.9 million of identifiable intangible assets, including $112.3 million of developed technology to be amortized over an average life of approximately 11 years and $28.6 million of IPR&D. The operating results of Boca are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and the operating results from the acquisition date of February 3, 2014 are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2014 . The Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014 reflect the acquisition of Boca, effective February 3, 2014 . Our measurement period adjustments were complete for Boca as of February 3, 2015 . Pro forma results of operations have not been presented because the effect of the Boca acquisition was not material. Sumavel ® DosePro ® On May 19, 2014 , the Company acquired the worldwide rights to Sumavel ® DosePro ® for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc. The Company is accounting for this transaction as a business combination in accordance with the relevant accounting literature. The Company acquired the product for consideration of $93.8 million , consisting of an upfront payment of $89.7 million and contingent cash consideration with an acquisition-date fair value of $4.1 million . See Note 7. Fair Value Measurements for further discussion of this contingent consideration. In addition, the Company provided Zogenix, Inc. with a $7.0 million non-interest bearing loan due 2023 for working capital needs and it assumed an existing third-party royalty obligation on net sales. Sumavel ® is a prescription medicine given with a needle-free delivery system to treat adults who have been diagnosed with acute migraine or cluster headaches. The fair values of the net identifiable assets acquired totaled $93.8 million , resulting in no goodwill. The amount of net identifiable assets acquired in connection with the Sumavel ® acquisition includes $90.0 million of identifiable developed technology intangible assets to be amortized over an average life of approximately 13 years . The operating results of Sumavel ® are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and the operating results from the acquisition date of May 19, 2014 are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2014 . The Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014 reflect the acquisition of Sumavel ® , effective May 19, 2014 . Our measurement period adjustments were complete for Sumavel as of May 19, 2015 . Pro forma results of operations have not been presented because the effect of the Sumavel ® acquisition was not material. Grupo Farmacéutico Somar Acquisition On July 24, 2014 , the Company acquired the representative shares of the capital stock of Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable, a leading privately-owned specialty pharmaceuticals company based in Mexico City, for $270.1 million in cash consideration. The fair values of the net identifiable assets acquired totaled $184.5 million , resulting in goodwill of $85.6 million , which was assigned to our International Pharmaceuticals segment. The amount of net identifiable assets acquired in connection with the Somar acquisition includes $167.9 million of identifiable intangible assets, including $148.3 million to be amortized over an average life of approximately 12 years and $19.6 million of IPR&D. The operating results of Somar are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and the operating results from the acquisition date of July 24, 2014 are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2014 . The Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014 reflect the acquisition of Somar, effective July 24, 2014 . Our measurement period adjustments were complete for Somar as of July 24, 2015 . Pro forma results of operations have not been presented because the effect of the Somar acquisition was not material. DAVA Pharmaceuticals, Inc. Acquisition On August 6, 2014 , the Company acquired DAVA Pharmaceuticals, Inc., a privately-held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals based in Fort Lee, New Jersey, for consideration of $590.1 million . The consideration consisted of cash consideration of $585.0 million and contingent cash consideration with an acquisition-date fair value of $5.1 million . See Note 7. Fair Value Measurements for further discussion of this contingent consideration. DAVA’s strategically-focused generics portfolio includes thirteen on-market products in a variety of therapeutic categories. The operating results of DAVA are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and the operating results from the acquisition date of August 6, 2014 are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2014 . The Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014 reflect the acquisition of DAVA, effective August 6, 2014 . Our measurement period adjustments were complete for DAVA as of August 6, 2015 . Pro forma results of operations have not been presented because the effect of the DAVA acquisition was not material. Natesto™ On December 9, 2014 , the Company acquired the rights to Natesto™ (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation. The Company will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto™. The Company is accounting for this transaction as a business combination in accordance with the relevant accounting literature. Natesto™ was approved by the U.S. Food and Drug Administration (FDA) in May 2014. On March 16, 2015, Endo announced the commercial availability of Natesto™. The Company acquired the product for consideration of $56.7 million , consisting of an upfront payment of $25.0 million , prepaid inventory of $5.0 million and contingent cash consideration with an acquisition-date fair value of $26.7 million , including the impact of a measurement period adjustment recorded during the first quarter of 2015. See Note 7. Fair Value Measurements for further discussion of this contingent consideration. The preliminary fair values of the net identifiable assets acquired totaled $56.7 million , resulting in no goodwill. The amount of net identifiable assets acquired in connection with the Natesto™ acquisition includes $51.7 million of developed technology to be amortized over 10 years . The net identifiable assets acquired in connection with the Natesto™ acquisition were fully written off during the third quarter of 2015. See Note 9. Goodwill and Other Intangibles for further discussion of this impairment. The operating results of Natesto™ are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 . There are no results included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2014 . The Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014 reflect the acquisition of Natesto™, effective December 9, 2014 . Our measurement period adjustments were complete for Natesto as of September 30, 2015. Pro forma results of operations have not been presented because the effect of the Natesto™ acquisition was not material. Auxilium Pharmaceuticals, Inc. On January 29, 2015 (the Auxilium Acquisition Date), the Company acquired all of the outstanding shares of common stock of Auxilium in a transaction valued at $2.6 billion , as enumerated in the table below. Pursuant to the terms of the Merger Agreement, of the 55.0 million outstanding Auxilium shares eligible to make an election, 94.9% elected to receive transaction consideration equal to 0.4880 Endo shares per Auxilium share (the Stock Election Consideration), 0.4% elected to receive 100% cash, which equated to $33.25 of cash per Auxilium share (the Cash Election Consideration) and 4.7% elected or defaulted to receive a mix of $16.625 in cash and 0.2440 Endo shares per Auxilium share (the Standard Election Consideration). The result of the elections led to an oversubscription of the Stock Election Consideration and, in accordance with the proration method described in the Merger Agreement and proxy statement/prospectus provided to Auxilium shareholders, each Auxilium share for which an election was made to receive the Stock Election Consideration was instead entitled to receive approximately 0.3448 Endo shares and $9.75 in cash. The acquisition consideration was as follows (in thousands, except for per share amounts): Number of Endo ordinary shares issued pursuant to the Merger Agreement 18,610 Endo share price on January 29, 2015 $ 81.64 Fair value of Endo ordinary shares issued to Auxilium stockholders $ 1,519,320 Cash distribution at closing (1) 1,021,864 Settlement of pre-existing relationships 28,400 Total acquisition consideration $ 2,569,584 __________ (1) Represents the cash paid directly to shareholders pursuant to the Merger Agreement, the fair value of Auxilium stock awards attributed to pre-combination services that were outstanding on the Auxilium Acquisition Date and settled in connection with the Auxilium acquisition, and amounts paid by Endo on behalf of Auxilium (including transactions costs incurred by Auxilium in connection with the acquisition and amounts paid to settle existing Auxilium indebtedness and related instruments). Auxilium is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specific patients’ needs. Auxilium, with a broad range of first- and second-line products across multiple indications, is an emerging leader in the men’s healthcare sector and has strategically focused its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. The Company believes Auxilium is highly complementary to Endo’s branded pharmaceuticals business. The Company further believes this transaction is well aligned with its growth strategy and the Company sees significant opportunities to leverage its leading presence in men’s health, as well as the Company’s R&D capabilities and financial resources to accelerate the growth of Auxilium’s XIAFLEX ® and its other products. While the Auxilium acquisition was primarily equity based, Endo also made changes to its existing debt structure to complete the transaction, as further described in Note 11. Debt . The operating results from the acquisition date of January 29, 2015 are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 . The Condensed Consolidated Balance Sheet as of September 30, 2015 reflects the acquisition of Auxilium, effective January 29, 2015 . The following table summarizes the fair values of the assets acquired and liabilities assumed at the Auxilium Acquisition Date (in thousands): January 29, 2015 Measurement period adjustments January 29, 2015 Cash and cash equivalents $ 115,973 $ — $ 115,973 Accounts receivable 75,849 — 75,849 Inventories 341,900 (44,699 ) 297,201 Prepaid expenses and other current assets 6,687 — 6,687 Property, plant and equipment 31,500 — 31,500 Intangible assets 2,838,000 (223,700 ) 2,614,300 Other assets 9,285 (999 ) 8,286 Total identifiable assets $ 3,419,194 $ (269,398 ) $ 3,149,796 Accounts payable and accrued expenses $ 120,553 $ 14,426 $ 134,979 Deferred income taxes 164,379 (29,370 ) 135,009 Convertible debt, including equity component (1) 571,132 — 571,132 Other liabilities 171,400 (4,320 ) 167,080 Total liabilities assumed $ 1,027,464 $ (19,264 ) $ 1,008,200 Net identifiable assets acquired $ 2,391,730 $ (250,134 ) $ 2,141,596 Goodwill 177,854 250,134 427,988 Net assets acquired $ 2,569,584 $ — $ 2,569,584 __________ (1) As further described in Note 11. Debt , this amount consists of $304.5 million and $266.6 million , representing the debt and equity components of the Auxilium convertible notes, respectively. The estimated fair value of the Auxilium assets acquired and liabilities assumed are provisional as of September 30, 2015 and are based on information that is currently available to the Company. Additional information is being gathered to finalize these provisional measurements, particularly with respect to intangible assets, accrued expenses, deferred income taxes and income taxes payable. Accordingly, the measurement of the Auxilium assets acquired and liabilities assumed may change significantly upon finalization of the Company’s valuations and completion of the purchase price allocation, both of which are expected to occur no later than one year from the acquisition date. During the three months ended September 30, 2015 , the Company recorded an additional $4.4 million loss on extinguishment of debt related to the conversion of Auxilium’s convertible debt, which occurred during the first quarter of 2015. This loss on extinguishment of debt represents differences between the fair values of the repurchased debt components and their carrying values. The valuation of the intangible assets acquired and related amortization periods are as follows: Valuation (in millions) Amortization period (in years) Developed Technology: XIAFLEX® $ 1,501.1 12 TESTOPEL® 584.3 15 Urology Retail 314.3 13 Other 128.9 15 Total $ 2,528.6 In Process Research & Development (IPR&D): XIAFLEX®—Cellulite $ 85.7 n/a Total $ 85.7 n/a Total other intangible assets $ 2,614.3 n/a The preliminary fair values of the developed technology and IPR&D assets were estimated using a discounted present value income approach. Under this method, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows (excess earnings) attributable solely to the intangible asset over its remaining useful life. To calculate fair value, the Company used cash flows discounted at rates ranging from 9% to 11% , which were considered appropriate given the inherent risks associated with each type of asset. The Company believes that the level and timing of cash flows appropriately reflect market participant assumptions. The goodwill recognized is attributable primarily to strategic and synergistic opportunities related to existing pharmaceutical businesses, the assembled workforce of Auxilium and other factors. Approximately $2.6 million of goodwill is expected to be deductible for income tax purposes. Deferred tax assets and liabilities are related primarily to the difference between the book basis and tax basis of identifiable intangible assets and inventory step-up. The Company recognized acquisition-related transaction costs associated with the Auxilium acquisition during the nine months ended September 30, 2015 totaling $23.1 million . These costs, which related primarily to bank fees, legal and accounting services, and fees for other professional services, are included in Acquisition-related and integration items in the accompanying Condensed Consolidated Statements of Operations . The amounts of Auxilium Revenue and Net income attributable to Endo International plc included in the Company’s Condensed Consolidated Statements of Operations from and including January 29, 2015 to September 30, 2015 are as follows (in thousands, except per share data): Revenue $ 237,807 Net loss attributable to Endo International plc (1) $ (257,597 ) Basic & diluted net (loss) per share $ (1.37 ) __________ (1) Net loss attributable to Endo International plc does not include any portion of the goodwill impairment charge recorded during the three months ended September 30, 2015 since it is not possible to distinguish the amount of the charge directly attributable to Auxilium. The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Auxilium had occurred on January 1, 2014 for the nine months ended September 30, 2015 and for the three and nine months ended September 30, 2014 . This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2014 , nor are they indicative of any future results. Nine Months Ended September 30, 2015 Three Months Ended September 30, 2014 Nine Months Ended September 30, 2014 Unaudited pro forma consolidated results (in thousands, except per share data): Revenue $ 2,218,596 $ 763,740 $ 1,998,967 Net loss attributable to Endo International plc $ (1,395,162 ) $ (308,003 ) $ (862,232 ) Basic net (loss) per share $ (7.42 ) $ (2.01 ) $ (5.96 ) Diluted net (loss) per share $ (7.42 ) $ (1.94 ) $ (5.53 ) These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Auxilium to reflect factually supportable adjustments that give effect to events that are directly attributable to the Auxilium acquisition assuming the Auxilium acquisition had occurred January 1, 2014 . These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by $5.9 million for the three months ended September 30, 2014 , and increased the expense by $1.1 million and $17.2 million for the nine months ended September 30, 2015 and September 30, 2014 , respectively. In addition, the adjustments include additional intangible amortization, net of tax, that would have been charged assuming the Company’s estimated fair value of the intangible assets, which increased the expense by $17.4 million for the three months ended September 30, 2014 . An adjustment to the amortization expense for the nine months ended September 30, 2015 and September 30, 2014 increased the expense by $6.2 million and $52.0 million , respectively. Acquisition of Par Pharmaceutical Holdings, Inc. On September 25, 2015 , the Company acquired Par for total consideration of $8.14 billion , including the assumption of Par debt. The consideration included 18,075,411 ordinary shares valued at $1.33 billion . The acquisition consideration was as follows (in thousands, except for per share amounts): Number of Endo ordinary shares issued pursuant to the Merger Agreement 18,075 Endo opening share price on September 25, 2015 $ 73.34 Fair value of Endo ordinary shares issued to Par stockholders (1) $ 1,325,651 Cash distribution at closing (2) 4,405,146 Fair value of Par debt settled at closing 2,404,857 Total acquisition consideration $ 8,135,654 __________ (1) Amounts do not recalculate due to rounding. (2) Amount includes transaction costs incurred by Par in connection with the acquisition. Par is a specialty pharmaceutical company that develops, manufactures and markets, innovative and cost-effective pharmaceuticals that help improve patient quality of life. Par offers a line of high-barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands. Par Sterile Products develops, manufactures and markets both branded and generic aseptic injectable pharmaceuticals. As a result, we believe Par’s business is highly complementary to Endo’s generic pharmaceuticals business. The Company also believes this transaction provides attractive long-term pipeline opportunities and significant financial synergies. The operating results from Par’s acquisition date of September 25, 2015 are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 . The Condensed Consolidated Balance Sheet as of September 30, 2015 reflects the acquisition of Par, effective September 25, 2015 . The following table summarizes the fair values of the assets acquired and liabilities assumed at the Par Acquisition Date (in thousands): September 25, 2015 Cash and cash equivalents $ 215,612 Accounts and other receivables 500,108 Inventories 359,000 Prepaid expenses and other current assets 34,582 Deferred income tax assets, current 6,387 Property, plant and equipment 239,983 Intangible assets 4,762,600 Other assets 11,421 Total identifiable assets $ 6,129,693 Accounts payable and accrued expenses $ 548,953 Deferred income tax liabilities 1,556,111 Other liabilities 14,286 Total liabilities assumed $ 2,119,350 Net identifiable assets acquired $ 4,010,343 Goodwill 4,125,311 Net assets acquired $ 8,135,654 The estimated fair value of the Par assets acquired and liabilities assumed are provisional as of September 30, 2015 and are based on information that is currently available to the Company. Additional information is being gathered to finalize these provisional measurements, particularly with respect to property, plant and equipment, intangible assets, inventory, accrued expenses, deferred income taxes and income taxes payable. Accordingly, the measurement of the Par assets acquired and liabilities assumed may change significantly upon finalization of the Company’s valuations and completion of the purchase price allocation, both of which are expected to occur no later than one year from the acquisition date. The valuation of the intangible assets acquired and related amortization periods are as follows: Valuation (in millions) Amortization period (in years) Developed Technology: Vasostrict TM $ 965.5 12 Aplisol® 185.1 12 Propafenone 152.6 12 Nascobal® 140.2 12 Bupropion 133.2 12 Other 1,093.3 12 Total $ 2,669.9 In Process Research & Development (IPR&D): Other $ 2,092.7 n/a Total $ 2,092.7 n/a Total other intangible assets $ 4,762.6 n/a The goodwill recognized is attributable primarily to strategic and synergistic opportunities related to existing pharmaceutical businesses, the assembled workforce of Par and other factors. Approximately $33.8 million of goodwill is expected to be deductible for income tax purposes. Deferred tax assets and liabilities are related primarily to the difference between the book basis and tax basis of identifiable intangible assets and inventory step-up. The Company recognized acquisition-related transaction costs associated with the Par acquisition during the three and nine months ended September 30, 2015 totaling $36.3 million and $45.9 million , respectively. These costs, which related primarily to bank fees, legal and accounting services, and fees for other professional services, are included in Acquisition-related and integration items in the accompanying Condensed Consolidated Statements of Operations . The amounts of Par Revenue and Net income attributable to Endo International plc included in the Company’s Condensed Consolidated Statements of Operations from and including September 25, 2015 to September 30, 2015 are as follows (in thousands, except per share data): Revenue $ 23,413 Net loss attributable to Endo International plc $ (17,441 ) |
